Attard: Uses this approach w/genotypes for monoallelic dels '14 ref https://t.co/fybeUCTAEJ #MAP16
7:02am September 23rd 2016 via Hootsuite
Attard: Chose 3 - mono-allelelic dels in 21q22, 8p21 (NKX3.1) and 10q22 (PTEN); pt muts in other genes #MAP16
6:59am September 23rd 2016 via Hootsuite
Attard: Discusses difficulty of CTC analysis in early-stage pts. Pre-analytic steps impt; ctDNA goes up in advanced disease #MAP16
6:58am September 23rd 2016 via Hootsuite
Attard: Use sequentially-collected plasma samples associated w/treatment resistance, only 6ng input. #MAP16
6:56am September 23rd 2016 via Hootsuite
Attard: mCRPC - after first-line castration, castration resistant prostate cancer. Hypothesis - sub-clonal muts that emerge #MAP16
6:55am September 23rd 2016 via Hootsuite
Gerhardt Attard (CRUK): Plasma AR analysis to direct the management of metastatic CRPC (PARADIGM) #MAP16
6:53am September 23rd 2016 via Hootsuite
Vanhaesebroeck: Q's: PI3Kdelta inh immunosupp but also heighten immune resp - but what dose? which cancers? What combinatios? #MAP16
6:48am September 23rd 2016 via Hootsuite
Vanhaesebroeck: PI3Kinh often leads to colitis; freq of AE, behaves like an immune modulator. Pneumonits, coiis, rash, inflam #MAP16
6:42am September 23rd 2016 via Hootsuite
Vanhaesebroeck: Immunology connection - PI3Kd inh blocks solid tumor; can a leukemia drug be used? Balance bet Treg, Th, CTL Killer #MAP16
6:40am September 23rd 2016 via Hootsuite
Vanhaesebroeck: When inhibited in malignant niche - go into circ, no direct cytotox, do not get stim back in lymph node #MAP16
6:36am September 23rd 2016 via Hootsuite
Vanhaesebroeck: CLL cells in-vitro - no direct cytotox. Showed delta is impt for signaling downstream. #MAP16
6:35am September 23rd 2016 via Hootsuite
Vanhaesebroeck For CLL, FL, SLL: in CLL have lymph node accumulation; Post-treatment, moves to circulation #MAP16
6:33am September 23rd 2016 via Hootsuite
Vanhaesebroeck: Delta: K Okkenhaug generated kinase-dead p110delta mice - reviews drugs developed as a result. ICOS Zydelig #MAP16
6:32am September 23rd 2016 via Hootsuite
Vanhaesebroeck: He cloned it in '97 (PNAS); mainly in leukocytes. alpha form amplified/mut in cancer. delta: immune, inflamm disease #MAP16
6:30am September 23rd 2016 via Hootsuite
Vanhaesebroeck: Cells can live w/only 5% PI3K activity; dev of resistance common. Combination Rx will be req'd. 1 Drug - p110delta #MAP16
6:29am September 23rd 2016 via Hootsuite
Vanhaesebroeck: Feels PI3K has been over-simplified; PIK3CA very freq in some ca's. PTEN opposite direction. PI3Kinh thus far modest #MAP16
6:28am September 23rd 2016 via Hootsuite
Vanhaesebroeck: PI 3-kinase is a family of enzymes, 3 classes; Clas I acts downstream of Tyr Kinases, GPCRs, GTPases #MAP16
6:26am September 23rd 2016 via Hootsuite
Bart Vanhaesebroeck (UCL London UK): PI3Kdelta a new kid on the block in cancer immunotherapy #MAP16
6:25am September 23rd 2016 via Hootsuite
Q: Failures? Sofia: What do you do about actionability? Br ca, lung have many Rx's; colorectal, other types is hard. #MAP16
5:52am September 23rd 2016 via Hootsuite
Q: (to Soria) Transloc vs ampl.? A: Poweful with transloc w/FGFR, not w/amplifications. Looking at interplay w/immunoRx #MAP16
5:47am September 23rd 2016 via Hootsuite
Paskorz: conclude that best Ab was DO-7 (DAKO) Ab on Leica Bond Max; cytoplasmic stain assoc'd w/TP53 LOF mutations #MAP16
5:44am September 23rd 2016 via Hootsuite
Paskorz: Cp 3 different ICH assays; devl. scoring for overexpr, complete absence; then cytoplasmic. Charted mut by IHC type #MAP16
5:41am September 23rd 2016 via Hootsuite
A lightning talk: Anna Paskorz (CURK) Opt p53 immunohistochemistry in HGSOC; 3 drugs in clinical trials (APR-246; Wee-1 inh AZD-1775) #MAP16
5:39am September 23rd 2016 via Hootsuite
Calvo: Feels that with WES/WGS, and ImmunoRx targets; improve drug coverage, more biomarkers, improve data analysis and outcomes #MAP16
5:31am September 23rd 2016 via Hootsuite
Calvo: Of 100 ca pts: 60% can ID driver; 50% can treat (now 30 of the 100); 50% will respond (15/100); 50% sustainable (7/100) #MAP16
5:29am September 23rd 2016 via Hootsuite
Calvo: Concl w/precision medicine limitations - ORR 50-80% (not universal); limited duration of effectiveness, with resistance #MAP16
5:28am September 23rd 2016 via Hootsuite
Calvo: Shows slide of 10 projects just in EU - for BrCa, Renal, HCC, Ewing, early Pr Ca. Outcomes listed - ID targets, mechanisms #MAP16
5:24am September 23rd 2016 via Hootsuite
Calvo: PCAWG - PancCancer Analysis of Whole Genomes; 2600 WGS T/N pairs is the goal. #MAP16
5:22am September 23rd 2016 via Hootsuite
Calvo: Showed a huge slide, worldwide, listing dozens of ICGC projecs. From Mexico, to Singapore, to Saudi Arabia, many others #MAP16
5:21am September 23rd 2016 via Hootsuite
Fabien Calvo (Gustave Roussey, France: From ICGC to ICGCmed #MAP16
5:19am September 23rd 2016 via Hootsuite
Siu: 'And patients welcome this idea'. Yesterday's NEJM https://t.co/CVtQsSmluW One example is ROS1-ers https://t.co/AX8EYPFpy9 #MAP16
Siu: Plan to use REDCap project from MSKCC; the deliverable is the data sharing. Showed a changed consent form for this. #MAP16
5:15am September 23rd 2016 via Hootsuite
Siu: BC Cancer Agency, and Princess Margaret / UHN, starting a Terry Fox CCC effort to share between Vancouver/Toronto #MAP16
5:14am September 23rd 2016 via Hootsuite
Siu: The goal is eventually to open up access. Cancer-LINQ ref: https://t.co/rUHux3H8Dm #MAP16
5:12am September 23rd 2016 via Hootsuite
Siu: Other projects - Project Genie; Orien; Oncology Precision Network; ASCO Cancer-LINQ has millions of EHRs moving to clin seq #MAP16
5:10am September 23rd 2016 via Hootsuite
Siu: Other initiatives - BRCA challenge, Cancer Gene Trust; sharing spec variants. both are open access #MAP16
5:09am September 23rd 2016 via Hootsuite
Siu: From NEJM 22 Sept from Staudt at the NCI: Toward a shared vision for cancer genomic data https://t.co/2Td3DhKKhI #MAP16
Siu: Conclude - no uniform approach for collecting data for precision medicine, even ethical procedures. #MAP16
5:06am September 23rd 2016 via Hootsuite
Siu: No 1 barrier to datasharing: "lack of funding"; the q is not only infrastructure, but who will standardize the data to share it #MAP16
5:05am September 23rd 2016 via Hootsuite
Siu: Shared demographic, and data capture results from ASCO slides; Most were research or dx/research; efficacy is nuanced result #MAP16
5:04am September 23rd 2016 via Hootsuite
Siu: n=59, ASCO abstract: https://t.co/ounzzDwjhu Heavy N.Am, EU; 'China was very difficult' #MAP16
5:00am September 23rd 2016 via Hootsuite
Siu: ... seq platforms, ethical concerns, funding sources, perceived barriers to datasharing. 97 questions #MAP16
4:59am September 23rd 2016 via Hootsuite
Siu: Performed a survey reported at ASCO - determining barriers to effective datasharing; looked at demographics, data collection... #MAP16
4:58am September 23rd 2016 via Hootsuite
Siu: Another - @GA4GH has many countries involved to create best-practices '16 Nature Med ref https://t.co/rPMKcvGl8t #MAP16
4:57am September 23rd 2016 via Hootsuite
Siu: So much data is buried; Cancer Moonshot Blue Ribbon draft quote - a National Cancer Data Ecosystem PDF: https://t.co/9AlWGpoaPd #MAP16
4:55am September 23rd 2016 via Hootsuite
Lilian Siu (Princess Margaret CC, Toronto, Canada) Datasharing initiatives in Precision Medicine #MAP16
4:51am September 23rd 2016 via Hootsuite
Soria: Showed several examples of improvement by disease type. Cholangiocarcinoma - PFS >6mo = 37%, clear Hazard R improvement #MAP16
4:49am September 23rd 2016 via Hootsuite
Soria: PFS comparison - null Hypothesis, PFS >1.3 = 15%. #Got PFS Ratio >1.3 = 33% Distribution: 20% of pts have PFS 2x MAP16
4:44am September 23rd 2016 via Hootsuite
Soria: MTB n=949; portrait n=844; n=411 had actionable. But matched Rx n=199, so only 20% rec'd matched Rx #MAP16
4:43am September 23rd 2016 via Hootsuite
Soria: By class: PI3K/AKT/mTOR, then ERBB2, FGFR. MOSCATO excluded pts with specific molecular defaults for which MTA avail. #MAP16
4:42am September 23rd 2016 via Hootsuite
